Michael E Mullendore
Overview
Explore the profile of Michael E Mullendore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El Touny L, Hose C, Connelly J, Harris E, Monks A, Dull A, et al.
Oncotarget
. 2021 Oct;
12(21):2114-2130.
PMID: 34676045
The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all...
2.
Hollingshead M, Stockwin L, Alcoser S, Newton D, Orsburn B, Bonomi C, et al.
BMC Genomics
. 2014 Jun;
15:393.
PMID: 24885658
Background: Development of cancer therapeutics partially depends upon selection of appropriate animal models. Therefore, improvements to model selection are beneficial. Results: Forty-nine human tumor xenografts at in vivo passages 1,...
3.
Morrison B, Mullendore M, Stockwin L, Borgel S, Hollingshead M, Newton D
Cancer Med
. 2014 Jan;
2(5):687-700.
PMID: 24403234
Oxyphenisatin (3,3-bis(4-hydroxyphenyl)-1H-indol-2-one) and several structurally related molecules have been shown to have in vitro and in vivo antiproliferative activity. This study aims to confirm and extend mechanistic studies by focusing...
4.
Kamiyama H, Rauenzahn S, Shim J, Karikari C, Feldmann G, Hua L, et al.
Clin Cancer Res
. 2013 Jan;
19(5):1139-46.
PMID: 23340293
Purpose: High-throughput chemosensitivity testing of low-passage cancer cell lines can be used to prioritize agents for personalized chemotherapy. However, generating cell lines from primary cancers is difficult because contaminating stromal...
5.
Glaros T, Stockwin L, Mullendore M, Smith B, Morrison B, Newton D
Cancer Chemother Pharmacol
. 2012 Apr;
70(1):207-12.
PMID: 22526412
Purpose: To establish whether NSC80467, a novel fused naphthquinone imidazolium, has a similar spectrum of activity to the well-characterized "survivin suppressant" YM155 and to extend mechanistic studies for this structural...
6.
Mullendore M, Koorstra J, Li Y, Offerhaus G, Fan X, Henderson C, et al.
Clin Cancer Res
. 2009 Mar;
15(7):2291-301.
PMID: 19258443
Purpose: Aberrant activation of the Notch signaling pathway is commonly observed in human pancreatic cancer, although the mechanism(s) for this activation has not been elucidated. Experimental Design: A panel of...
7.
Habbe N, Koorstra J, Mendell J, Offerhaus G, Ryu J, Feldmann G, et al.
Cancer Biol Ther
. 2008 Dec;
8(4):340-6.
PMID: 19106647
Background: Intraductal papillary mucinous neoplasms (IPMNs) are non-invasive precursor lesions of pancreatic cancer. Misexpression of microRNAs (miRNAs) is commonly observed in pancreatic adenocarcinoma. In contrast, miRNA abnormalities in pancreatic cancer...
8.
Kassauei K, Habbe N, Mullendore M, Karikari C, Maitra A, Feldmann G
Int J Gastrointest Cancer
. 2007 Sep;
37(2-3):57-64.
PMID: 17827523
Background: Somatic mutations of mitochondrial DNA (mtDNA) are increasingly being recognized in many human cancers, but automated sequencing of 16.5 kb of DNA poses an onerous task. We have recently...
9.
Agarwal S, Burns A, Sukhodolets K, Kennedy P, Obungu V, Hickman A, et al.
Ann N Y Acad Sci
. 2004 May;
1014:189-98.
PMID: 15153434
Multiple endocrine neoplasia type 1 (MEN1), among all syndromes, causes tumors in the highest number of tissue types. Most of the tumors are hormone producing (e.g., parathyroid, enteropancreatic endocrine, anterior...